MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107. A total of 62 filers reported holding MEREO BIOPHARMA GROUP PLC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $7,589 | -5.7% | 10,735 | 0.0% | 0.00% | – |
| Q4 2022 | $8,051 | -10.5% | 10,735 | 0.0% | 0.00% | – |
| Q3 2022 | $9,000 | -25.0% | 10,735 | 0.0% | 0.00% | – |
| Q2 2022 | $12,000 | 0.0% | 10,735 | 0.0% | 0.00% | – |
| Q1 2022 | $12,000 | -29.4% | 10,735 | 0.0% | 0.00% | -100.0% |
| Q4 2021 | $17,000 | -34.6% | 10,735 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $26,000 | -23.5% | 10,735 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $34,000 | -5.6% | 10,735 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $36,000 | -32.1% | 10,735 | -27.1% | 0.00% | -50.0% |
| Q4 2020 | $53,000 | -63.2% | 14,735 | -73.1% | 0.00% | -71.4% |
| Q3 2020 | $144,000 | -14.3% | 54,773 | 0.0% | 0.01% | -30.0% |
| Q2 2020 | $168,000 | +115.4% | 54,773 | -26.7% | 0.01% | +66.7% |
| Q1 2020 | $78,000 | -54.4% | 74,773 | +43.2% | 0.01% | -33.3% |
| Q4 2019 | $171,000 | -26.6% | 52,199 | -33.3% | 0.01% | -40.0% |
| Q3 2019 | $233,000 | +19.5% | 78,207 | +1.4% | 0.02% | +36.4% |
| Q2 2019 | $195,000 | – | 77,152 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 6,220,938 | $16,299,000 | 0.94% |
| Boxer Capital, LLC | 4,029,649 | $10,558,000 | 0.36% |
| DAFNA Capital Management LLC | 199,425 | $522,000 | 0.17% |
| J. Goldman & Co LP | 443,517 | $1,162,000 | 0.08% |
| Ikarian Capital, LLC | 1,196,308 | $688,000 | 0.05% |
| HHLR ADVISORS, LTD. | 1,598,185 | $4,187,000 | 0.03% |
| BOOTHBAY FUND MANAGEMENT, LLC | 133,634 | $350,000 | 0.02% |
| F3Logic, LLC | 255 | $668,000 | 0.02% |
| Schonfeld Strategic Advisors LLC | 343,195 | $899,000 | 0.02% |
| CSS LLC/IL | 54,773 | $144,000 | 0.01% |